KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Notes Payables (2016 - 2025)

Historic Notes Payables for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $3.8 billion.

  • AbbVie's Notes Payables changed N/A to $3.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 billion, marking a year-over-year change of. This contributed to the annual value of $1.0 million for FY2022, which is 9285.71% down from last year.
  • As of Q3 2025, AbbVie's Notes Payables stood at $3.8 billion.
  • AbbVie's 5-year Notes Payables high stood at $3.8 billion for Q3 2025, and its period low was $1.0 million during Q4 2022.
  • In the last 5 years, AbbVie's Notes Payables had a median value of $13.0 million in 2021 and averaged $534.6 million.
  • Its Notes Payables has fluctuated over the past 5 years, first plummeted by 9285.71% in 2022, then soared by 5300000.0% in 2025.
  • Quarter analysis of 5 years shows AbbVie's Notes Payables stood at $14.0 million in 2021, then crashed by 92.86% to $1.0 million in 2022, then surged by 100.0% to $2.0 million in 2023, then skyrocketed by 50.0% to $3.0 million in 2024, then surged by 126233.33% to $3.8 billion in 2025.
  • Its Notes Payables stands at $3.8 billion for Q3 2025, versus $2.0 billion for Q2 2025 and $1.6 billion for Q1 2025.